



EPICS

CONFERENCE COVERAGE: SABCS 2020 – FOCUS ON BREAST CANCER

December 14, 2020

FULL REPORT

- > On December 14, 2020, following the San Antonio Breast Cancer Symposium (SABCS), Aptitude Health brought together a group of scientists and clinical investigators with expertise in breast cancer to attend the Emerging Paradigms in Care Series (EPICS) Congress Coverage meeting
- > The goal of the expert panel was to critique and debate new evidence in breast cancer and gain strategic insight into the most impactful abstracts from the SABCS meeting with respect to shaping current research directions and/or changing the scope of practical clinical care

FACULTY EXPERTS

Chair:

Adam Brufsky, MD, PhD



Nadia Harbeck, MD, PhD



Peter A. Kaufman, MD



Miguel Martin, MD, PhD



Joyce A. O'Shaughnessy, MD



Mark Pegram, MD



Hope Rugo, MD

Time (EST)	Topic	Speaker/Moderator
9.00 AM – 9.10 AM	Welcome and Introductions	Adam Brufsky, MD, PhD
9.10 AM – 9.20 AM	CDK4/6 Inhibitors and Other Targeted Agents for ER+ Breast Cancer	Miguel Martin, MD, PhD
9.20 AM – 9.35 AM	Key Questions and Topics for Discussion	All
9.35 AM – 9.40 AM	Key Takeaways	Adam Brufsky, MD, PhD
9.40 AM – 9.50 AM	Chemotherapy and Endocrine Therapy for ER+ Breast Cancer	Peter A. Kaufman, MD
9.50 AM – 10.05 AM	Key Questions and Topics for Discussion	All
10.05 AM – 10.10 AM	Key Takeaways	Adam Brufsky, MD, PhD
10.10 AM – 10.20 AM	New Therapeutic Approaches for Early Stage and Metastatic HER2+ Breast Cancer	Joyce O’Shaughnessy, MD
10.20 AM – 10.35 AM	Key Questions and Topics for Discussion	All
10.35 AM – 10.40 AM	Key Takeaways	Adam Brufsky, MD, PhD
10.40 AM – 10.50 AM	BREAK	
10.50 AM – 11.00 AM	Immunotherapy and Cytotoxic Therapies for TNBC	Nadia Harbeck, MD, PhD/Hope Rugo, MD
11.00 AM – 11.15 AM	Key Questions and Topics for Discussion	All
11.15 AM – 11.20 AM	Key Takeaways	Adam Brufsky, MD, PhD
11.20 AM – 11.30 AM	Other Novel Therapeutic Approaches for Breast Cancer	Mark Pegram, MD
11.30 AM – 11.45 AM	Key Questions and Topics for Discussion	All
11.45 AM – 12.00 PM	Key Takeaways and Closing Remarks	Adam Brufsky, MD, PhD

 A large, stylized logo consisting of several thick, dark blue curved lines that form a circular, sunburst-like pattern. The lines are arranged in a way that they appear to be radiating from a central point, creating a sense of movement and energy.

EPICS

CDK4/6 Inhibitors and Other Targeted Agents for ER+ Breast Cancer

MIGUEL MARTIN, MD, PHD

CDK4/6 INHIBITORS AND OTHER TARGETED AGENTS FOR ER+ BREAST CANCER – ABSTRACTS (1/10)

- > **GS1-01.** Primary outcome analysis of invasive disease-free survival for monarchE: abemaciclib

CONTACT US TO OBTAIN A COPY OF THE FULL REPORT

CDK4/6 INHIBITORS AND OTHER TARGETED AGENTS FOR ER+ BREAST CANCER – ABSTRACTS (2/10)

- > PD2-01. High Ki-67 as a biomarker for identifying patients with high risk early breast cancer treated

CONTACT US TO OBTAIN A COPY OF THE FULL REPORT

CDK4/6 INHIBITORS AND OTHER TARGETED AGENTS FOR ER+ BREAST CANCER – ABSTRACTS (3/10)

- > **GS1-02.** Phase III study of palbociclib combined with endocrine therapy (ET) in patients with

CONTACT US TO OBTAIN A COPY OF THE FULL REPORT

CDK4/6 INHIBITORS AND OTHER TARGETED AGENTS FOR ER+ BREAST CANCER – ABSTRACTS (4/10)

- > PD2-03. Treatment persistence and dose modifications in the PALLAS trial: PALbociclib

CONTACT US TO OBTAIN A COPY OF THE FULL REPORT

CDK4/6 INHIBITORS AND OTHER TARGETED AGENTS FOR ER+ BREAST CANCER – ABSTRACTS (5/10)

- > **GS1-04.** Correlative biomarker analysis of intrinsic subtypes and efficacy across the MONALEESA

CONTACT US TO OBTAIN A COPY OF THE FULL REPORT

CDK4/6 INHIBITORS AND OTHER TARGETED AGENTS FOR ER+ BREAST CANCER – ABSTRACTS (6/10)

- > **GS4-02.** E2112: randomized phase 3 trial of endocrine therapy plus entinostat/placebo in patients

CONTACT US TO OBTAIN A
COPY OF THE FULL REPORT

CDK4/6 INHIBITORS AND OTHER TARGETED AGENTS FOR ER+ BREAST CANCER – ABSTRACTS (7/10)

- > **PD1-01.** Open-label, randomized, phase 2 study of sapanisertib (TAK-228/MLN0128) in

CONTACT US TO OBTAIN A COPY OF THE FULL REPORT

CDK4/6 INHIBITORS AND OTHER TARGETED AGENTS FOR ER+ BREAST CANCER – ABSTRACTS (8/10)

- > **PD1-05.** Latest findings from the breast cancer cohort in SUMMIT – a phase 2 “basket:” trial of

CONTACT US TO OBTAIN A COPY OF THE FULL REPORT

CDK4/6 INHIBITORS AND OTHER TARGETED AGENTS FOR ER+ BREAST CANCER – ABSTRACTS (9/10)

- > **PD2-05.** Randomized phase II trial to evaluate alisertib alone or combined with fulvestrant for

CONTACT US TO OBTAIN A COPY OF THE FULL REPORT

CDK4/6 INHIBITORS AND OTHER TARGETED AGENTS FOR ER+ BREAST CANCER – ABSTRACTS (10/10)

- > **PD2-04.** Updated overall survival (OS) results from the phase III MONALEESA-7 trial of pre- or

CONTACT US TO OBTAIN A COPY OF THE FULL REPORT

CDK4/6 INHIBITORS AND OTHER TARGETED AGENTS FOR ER+ BREAST CANCER – DISCUSSION (1/4)

- > It is unclear why the monarchE trial showed a significant improvement in iDFS with the addition of

CONTACT US TO OBTAIN A COPY OF THE FULL REPORT

CDK4/6 INHIBITORS AND OTHER TARGETED AGENTS FOR ER+ BREAST CANCER – DISCUSSION (2/4)

- > Accumulating data have supported the prognostic ability of Ki67 in HR+ breast cancer, and the data from

CONTACT US TO OBTAIN A COPY OF THE FULL REPORT

CDK4/6 INHIBITORS AND OTHER TARGETED AGENTS FOR ER+ BREAST CANCER – DISCUSSION (3/4)

- > The 46% ORR achieved with neratinib plus trastuzumab plus fulvestrant in HR+, HER2-mutated

CONTACT US TO OBTAIN A COPY OF THE FULL REPORT

CDK4/6 INHIBITORS AND OTHER TARGETED AGENTS FOR ER+ BREAST CANCER – DISCUSSION (4/4)

- > The results from the phase III ECOG 2112 trial evaluating exemestane with or without entinostat

CONTACT US TO OBTAIN A COPY OF THE FULL REPORT

 A large, dark blue stylized logo on the left side of the slide, consisting of several thick, curved lines that form a circular, sunburst-like pattern.

EPICS

**Chemotherapy and
Endocrine Therapy for ER+
Breast Cancer**

PETER A. KAUFMAN, MD

CHEMOTHERAPY AND ENDOCRINE THERAPY FOR ER+ BREAST CANCER – ABSTRACTS (1/6)

- > **GS3-00.** SWOG S1007: adjuvant trial of randomized ER+ patients who had a Recurrence Score

CONTACT US TO OBTAIN A COPY OF THE FULL REPORT

CHEMOTHERAPY AND ENDOCRINE THERAPY FOR ER+ BREAST CANCER – ABSTRACTS (2/6)

- > **GS4-04.** Endocrine therapy alone in patients with intermediate or high-risk luminal early breast

CONTACT US TO OBTAIN A COPY OF THE FULL REPORT

CHEMOTHERAPY AND ENDOCRINE THERAPY FOR ER+ BREAST CANCER – ABSTRACTS (3/6)

- > **GS4-01.** Results from CONTESSA: A phase 3 study of tasetaxel plus a reduced dose of

CONTACT US TO OBTAIN A COPY OF THE FULL REPORT

CHEMOTHERAPY AND ENDOCRINE THERAPY FOR ER+ BREAST CANCER – ABSTRACTS (4/6)

- > **PD8-06.** Phase I/II trial of H3B-6545, a novel selective estrogen receptor covalent antagonist

CONTACT US TO OBTAIN A COPY OF THE FULL REPORT

CHEMOTHERAPY AND ENDOCRINE THERAPY FOR ER+ BREAST CANCER – ABSTRACTS (5/6)

- > **PD8-08.** A Phase 1/2 study of SAR439859, an oral selective estrogen receptor (ER) degrader

CONTACT US TO OBTAIN A COPY OF THE FULL REPORT

CHEMOTHERAPY AND ENDOCRINE THERAPY FOR ER+ BREAST CANCER – ABSTRACTS (6/6)

- > **PD8-07.** Pharmacodynamic analysis from a Phase 1 study of rintodestrant (G1T48), an oral

CONTACT US TO OBTAIN A COPY OF THE FULL REPORT

CHEMOTHERAPY AND ENDOCRINE THERAPY FOR ER+ BREAST CANCER – DISCUSSION (1/3)

- > Results from the RxPONDER and ADAPT trials provide complementary and helpful information with

CONTACT US TO OBTAIN A COPY OF THE FULL REPORT

CHEMOTHERAPY AND ENDOCRINE THERAPY FOR ER+ BREAST CANCER – DISCUSSION (2/3)

- > The ADAPT-CYCLE trial will be comparing treatment with adjuvant endocrine therapy plus a

CONTACT US TO OBTAIN A COPY OF THE FULL REPORT

CHEMOTHERAPY AND ENDOCRINE THERAPY FOR ER+ BREAST CANCER – DISCUSSION (3/3)

- > Although the CONTESSA trial showed an improvement in PFS and ORR with the combination of

CONTACT US TO OBTAIN A COPY OF THE FULL REPORT

 A large, stylized logo consisting of several thick, dark blue curved lines that form a circular, sunburst-like pattern. The lines are arranged in a way that they appear to be radiating from a central point, creating a sense of movement and energy.

EPICS

New Therapeutic Approaches for Early Stage and Metastatic HER2+ Breast Cancer

JOYCE O'SHAUGHNESSY, MD

NEW THERAPEUTIC APPROACHES FOR EARLY STAGE AND METASTATIC HER2+ BREAST CANCER – ABSTRACTS (1/8)

- > **PD3-11.** A randomized, open-label, phase III trial of pertuzumab re-treatment in HER2-positive.

CONTACT US TO OBTAIN A COPY OF THE FULL REPORT

NEW THERAPEUTIC APPROACHES FOR EARLY STAGE AND METASTATIC HER2+ BREAST CANCER – ABSTRACTS (2/8)

- > **PD13-09.** Impact of neratinib on outcomes in HER2-positive metastatic breast cancer patients with

CONTACT US TO OBTAIN A COPY OF THE FULL REPORT

NEW THERAPEUTIC APPROACHES FOR EARLY STAGE AND METASTATIC HER2+ BREAST CANCER – ABSTRACTS (3/8)

- > **PD3-08.** Tucatinib vs placebo in combination with trastuzumab and capecitabine for patients with

CONTACT US TO OBTAIN A COPY OF THE FULL REPORT

NEW THERAPEUTIC APPROACHES FOR EARLY STAGE AND METASTATIC HER2+ BREAST CANCER – ABSTRACTS (4/8)

- > **PD13-04.** Impact of tucatinib on health-related quality of life in patients with HER2+ metastatic

CONTACT US TO OBTAIN A COPY OF THE FULL REPORT

NEW THERAPEUTIC APPROACHES FOR EARLY STAGE AND METASTATIC HER2+ BREAST CANCER – ABSTRACTS (5/8)

- > **PD3-06.** Updated results from DESTINY-Breast01, a phase 2 trial of Trastuzumab Deruxtecan (T-

CONTACT US TO OBTAIN A COPY OF THE FULL REPORT

NEW THERAPEUTIC APPROACHES FOR EARLY STAGE AND METASTATIC HER2+ BREAST CANCER – ABSTRACTS (6/8)

- > PD3-07. Trastuzumab deruxtecan (T-DXd: DS-8201) with nivolumab in patients with HER2-

CONTACT US TO OBTAIN A COPY OF THE FULL REPORT

NEW THERAPEUTIC APPROACHES FOR EARLY STAGE AND METASTATIC HER2+ BREAST CANCER – ABSTRACTS (7/8)

- > **PD1-7.** A Phase 2 study of poziotinib in patients with HER2-positive metastatic breast cancer

CONTACT US TO OBTAIN A COPY OF THE FULL REPORT

NEW THERAPEUTIC APPROACHES FOR EARLY STAGE AND METASTATIC HER2+ BREAST CANCER – ABSTRACTS (8/8)

- > **PD3-03.** Continued efficacy of neratinib in patients with HER2-positive early-stage breast cancer:

CONTACT US TO OBTAIN A COPY OF THE FULL REPORT

NEW THERAPEUTIC APPROACHES FOR EARLY STAGE AND METASTATIC HER2+ BREAST CANCER – DISCUSSION (1/3)

- > The updated data from the DESTINY Breast-01 trial showing a 3-month extension in median PFS

CONTACT US TO OBTAIN A COPY OF THE FULL REPORT

NEW THERAPEUTIC APPROACHES FOR EARLY STAGE AND METASTATIC HER2+ BREAST CANCER – DISCUSSION (2/3)

> The subset analyses from the ExteNET trial were considered suggestive and helpful, and could be

CONTACT US TO OBTAIN A
COPY OF THE FULL REPORT

NEW THERAPEUTIC APPROACHES FOR EARLY STAGE AND METASTATIC HER2+ BREAST CANCER – DISCUSSION (3/3)

- > Dose escalation is considered a very effective way to manage patients initiating treatment with

CONTACT US TO OBTAIN A COPY OF THE FULL REPORT

 A large, stylized logo consisting of several thick, dark blue curved lines that form a circular, sunburst-like pattern. The lines are arranged in a way that they appear to be radiating from a central point, creating a sense of movement and energy.

EPICS

Immunotherapy and Cytotoxic Therapies for TNBC

NADIA HARBECK, MD, PHD

HOPE RUGO, MD

IMMUNOTHERAPY AND CYTOTOXIC THERAPIES FOR TNBC – ABSTRACTS (1/7)

EPICS

- > **GS3-01.** Additional efficacy endpoints from the phase 3 KEYNOTE-355 study of pembrolizumab

CONTACT US TO OBTAIN A COPY OF THE FULL REPORT

IMMUNOTHERAPY AND CYTOTOXIC THERAPIES FOR TNBC – ABSTRACTS (2/7)

- > **PD14-05.** Genomic profiling and clinical outcomes with first-line atezolizumab and nab-paclitaxel in

CONTACT US TO OBTAIN A COPY OF THE FULL REPORT

IMMUNOTHERAPY AND CYTOTOXIC THERAPIES FOR TNBC – ABSTRACTS (3/7)

- > **GS3-02.** Patient-reported outcomes (PROs) from the Phase 3 IMpassion031 trial of neoadjuvant

CONTACT US TO OBTAIN A COPY OF THE FULL REPORT

IMMUNOTHERAPY AND CYTOTOXIC THERAPIES FOR TNBC – ABSTRACTS (4/7)

- > **GS3-04.** Double-blind placebo (PBO)-controlled randomized phase III trial evaluating first-line

CONTACT US TO OBTAIN A COPY OF THE FULL REPORT

IMMUNOTHERAPY AND CYTOTOXIC THERAPIES FOR TNBC – ABSTRACTS (5/7)

- > **GS3-06.** Biomarker evaluation in the phase 3 ASCENT study of sacituzumab govitecan versus

CONTACT US TO OBTAIN A COPY OF THE FULL REPORT

IMMUNOTHERAPY AND CYTOTOXIC THERAPIES FOR TNBC – ABSTRACTS (6/7)

- > **PD13-07.** Subgroup analysis of patients with brain metastases from the phase 3 ASCENT study of

CONTACT US TO OBTAIN A COPY OF THE FULL REPORT

IMMUNOTHERAPY AND CYTOTOXIC THERAPIES FOR TNBC – ABSTRACTS (7/7)

- > **PD1-06.** Trilaciclib improves overall survival when given with gemcitabine/carboplatin in patients

CONTACT US TO OBTAIN A COPY OF THE FULL REPORT

IMMUNOTHERAPY AND CYTOTOXIC THERAPIES FOR TNBC – DISCUSSION (1/3)

- > It remains unclear why pembrolizumab improved PFS in combination with paclitaxel in KEYNOTE-355

CONTACT US TO OBTAIN A COPY OF THE FULL REPORT

IMMUNOTHERAPY AND CYTOTOXIC THERAPIES FOR TNBC – DISCUSSION (2/3)

- > In countries where both atezolizumab and pembrolizumab are approved for mTNBC, experts were

CONTACT US TO OBTAIN A COPY OF THE FULL REPORT

IMMUNOTHERAPY AND CYTOTOXIC THERAPIES FOR TNBC – DISCUSSION (3/3)

- > The phase II data with trilaciclib in combination with gemcitabine plus carboplatin were considered

CONTACT US TO OBTAIN A
COPY OF THE FULL REPORT

 A large, stylized logo consisting of several thick, dark blue curved lines that form a circular, sunburst-like pattern. The lines are arranged in a way that they appear to be radiating from a central point, creating a sense of movement and energy.

EPICS

Other Novel Therapeutic Approaches for Breast Cancer

MARK PEGRAM, MD

OTHER NOVEL THERAPEUTIC APPROACHES FOR BREAST CANCER – ABSTRACTS (1/4)

- > **PD1.09.** Safety and efficacy results from the phase 1/2 study of U3-1402, a human epidermal

CONTACT US TO OBTAIN A
COPY OF THE FULL REPORT

OTHER NOVEL THERAPEUTIC APPROACHES FOR BREAST CANCER – ABSTRACTS (2/4)

- > **PD1-10.** Evaluation of SGN-LIV1a followed by AC in high-risk HER2 negative stage II/III breast

CONTACT US TO OBTAIN A COPY OF THE FULL REPORT

OTHER NOVEL THERAPEUTIC APPROACHES FOR BREAST CANCER – ABSTRACTS (3/4)

- > **PD10-12.** Genomic analysis from the talazoparib beyond BRCA clinical trial: Homologous

CONTACT US TO OBTAIN A COPY OF THE FULL REPORT

OTHER NOVEL THERAPEUTIC APPROACHES FOR BREAST CANCER – ABSTRACTS (4/4)

- > **PD14-02.** Biomarkers predicting response to durvalumab combined with olaparib in the

CONTACT US TO OBTAIN A COPY OF THE FULL REPORT

OTHER NOVEL THERAPEUTIC APPROACHES FOR BREAST CANCER – DISCUSSION (1/3)

- > pCR rates with SGN-LIV1a (ladiratuzumab vedotin) were similar to those achieved with paclitaxel in

CONTACT US TO OBTAIN A COPY OF THE FULL REPORT

OTHER NOVEL THERAPEUTIC APPROACHES FOR BREAST CANCER – DISCUSSION (2/3)

- > The finding that responses were observed with talazoparib in patients with *PALB2*-mutated MBC

CONTACT US TO OBTAIN A COPY OF THE FULL REPORT

OTHER NOVEL THERAPEUTIC APPROACHES FOR BREAST CANCER – DISCUSSION (3/3)

- > Preliminary data with the anti-HER3 ADC U3-1402 suggest promising activity, with some durable

CONTACT US TO OBTAIN A COPY OF THE FULL REPORT



US Headquarters

5901-C Peachtree Dunwoody Road NE
Suite 200, Atlanta, GA 30328, US

EU Headquarters

Wilhelmina van Pruisenweg 104
2595 AN The Hague, the Netherlands

aptitudehealth.com

